Evidence-based and value-based formulary guidelines

被引:56
作者
Neumann, PJ [1 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Program Econ Evaluat Med Technol, Ctr Risk Anal, Boston, MA 02115 USA
关键词
D O I
10.1377/hlthaff.23.1.124
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Health plans and hospitals have long used drug formularies, but the processes by which formulary committees made decisions have typically lacked transparency and scientific rigor. A growing number of organizations have begun, implementing formulary guidelines issued by the Academy of Managed Care Pharmacy (AMCP). These guidelines call for health plans to request formally that drug companies present a standardized "dossier" that contains detailed information not only on the drug's effectiveness and safety but also on its economic value relative to alternative therapies. This paper describes the guidelines, reviews progress to date, and analyzes several critical issues for the future.
引用
收藏
页码:124 / 134
页数:11
相关论文
共 47 条
[1]  
*AC MAN CAR PHARM, 2003, FORM FORM SUBM
[2]  
*AMCP, 2002, RESP COMM REG AMCPS
[3]  
*AMCP, 2003, YEAR REV 2002 2003
[4]   Using economic evaluations to make formulary coverage decisions - So much for guidelines [J].
Anis, AH ;
Gagnon, Y .
PHARMACOECONOMICS, 2000, 18 (01) :55-62
[5]  
ATHERLY DE, 2001, VALUE HEALTH, V4, P52
[6]  
AVEY, 14 ANN M AMCP
[7]  
AVEY, AMCPS FORMAT FORMULA
[8]  
AVEY S, 2002, 14 ANN M AMCP SALT L
[9]  
CROSS MA, 2002, MANAGED CARE NOV, P32
[10]   From guidance to practice: Why NICE is not enough [J].
Dent, THS ;
Sadler, M .
BRITISH MEDICAL JOURNAL, 2002, 324 (7341) :842-845